Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 1;22(1):9.
doi: 10.1186/s12981-024-00690-9.

Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data

Yiyang Liu  1 , Rebecca J Fisk-Hoffman  2 , Maitri Patel  2 , Robert L Cook  2 , Mattia Prosperi  2
Affiliations

Receipt of long-acting injectable antiretroviral therapy among people with HIV in Southern US states: an assessment using electronic health records and claims data

Yiyang Liu et al. AIDS Res Ther. .

Abstract

Background: In January 2021, the United States (US) Food and Drug Administration (FDA) approved the first long-acting injectable antiretroviral therapy (LAI ART) regimen for the treatment of HIV providing an alternative to daily oral regimens. We analyzed electronic health records (EHRs) to provide real-world evidence of demographic and clinical characteristics associated with the receipt of LAI ART among people with HIV (PWH).

Methods: Leveraging EHRs from a large clinical research network in the Southern US - OneFlorida + linked with Medicaid (updated to 08/2022) - we identified a cohort of PWH who have been prescribed at least one dose of LAI ART since January 2021 and characterized their demographics, clinical characteristics, and HIV care outcomes.

Results: A total of 233 LAI ART recipients were identified: 56.7% female, 45.1% aged 30 to 44, 51.3% non-Hispanic Black, 78.1% on Medicaid and 4.7% on private insurance. Approximately three-quarters of injections (71.2%) were received within 37 days of the previous dose, and 84.4% were received within 67 days. About 8% of LAI ART recipients did not have optimal care engagement the year before LAI ART initiation; one in five recipients had a diagnosis of alcohol or substance use disorder in lifetime. All achieved viral suppression (< 50 copies/mL) before starting LAI ART. Of a subset of patients with HIV viral load test records, only 1 record of virologic failure (viral load > 200 copies/ml) was observed after the initiation of LAI ART.

Discussion: There has been an increasing trend of LAI ART initiation since approval. People with suboptimal care engagement and with substance use disorder in lifetime were not excluded from LAI ART treatment.

Keywords: Cabotegravir/Rilpivirine; Electronic health records; HIV; Long-acting antiretroviral therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors received research funding from Merck via its Investigator-Initiated Studies Program and received travel reimbursement from Merck to present related results at conferences.

Figures

Fig. 1
Fig. 1
Trends in LAI initiation rate (cumulative) after FDA approval date Denominator: total number of PWH who had clinical encounter between 2021 and 2022 Grey bar represents the 95% confidence interval
See this image and copyright information in PMC

References

    1. Trickey A, Sabin CA, Burkholder G, Crane H, d’Arminio Monforte A, Egger M, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295–307. - PMC - PubMed
    1. Centers for Disease Control and Prevention. Undetectable = Untransmittable. 2024 [cited 2024 Nov 20]; https://www.cdc.gov/global-hiv-tb/php/our-approach/undetectable-untransm...
    1. Crepaz N, Song R, Lyss S, Hall HI. Trends in Time From HIV Diagnosis to First Viral Suppression Following Revised US HIV Treatment Guidelines, 2012–2017. J Acquir Immune Defic Syndr. 2020;85(1):46–50. - PMC - PubMed
    1. Clay PG, Nag S, Graham CM, Narayanan S. Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens. Med (Baltim). 2015;94(42):e1677. - PMC - PubMed
    1. Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016;13(11):e1002183. - PMC - PubMed

Substances

LinkOut - more resources